NASDAQ:OBIO Orchestra BioMed (OBIO) Stock Price, News & Analysis $6.23 +0.77 (+14.10%) (As of 11/5/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Orchestra BioMed Stock (NASDAQ:OBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Orchestra BioMed alerts:Sign Up Key Stats Today's Range$5.41▼$6.2450-Day Range$4.61▼$6.7052-Week Range$4.22▼$11.69Volume67,050 shsAverage Volume76,347 shsMarket Capitalization$235.68 millionP/E RatioN/ADividend YieldN/APrice Target$15.75Consensus RatingBuy Company OverviewOrchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Read More… Countdown to the biggest trade of my 25 yr career (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Orchestra BioMed Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks44th Percentile Overall ScoreOBIO MarketRank™: Orchestra BioMed scored higher than 44% of companies evaluated by MarketBeat, and ranked 641st out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOrchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOrchestra BioMed has only been the subject of 1 research reports in the past 90 days.Read more about Orchestra BioMed's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.67) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchestra BioMed is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchestra BioMed is -3.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchestra BioMed has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Orchestra BioMed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.18% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Orchestra BioMed has recently decreased by 9.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrchestra BioMed does not currently pay a dividend.Dividend GrowthOrchestra BioMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.18% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Orchestra BioMed has recently decreased by 9.41%, indicating that investor sentiment is improving significantly. News and Social Media0.8 / 5News SentimentN/A News SentimentOrchestra BioMed has a news sentiment score of -0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Orchestra BioMed insiders have sold 415.62% more of their company's stock than they have bought. Specifically, they have bought $26,875.00 in company stock and sold $138,573.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of Orchestra BioMed is held by insiders.Percentage Held by Institutions53.55% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Orchestra BioMed's insider trading history. Receive OBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter. Email Address OBIO Stock News HeadlinesHC Wainwright & Co. Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy RecommendationAugust 23, 2024 | msn.comMDT Aug 2024 81.000 putAugust 15, 2024 | uk.finance.yahoo.comWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.November 5, 2024 | Porter & Company (Ad)MDT Aug 2024 87.000 callAugust 15, 2024 | uk.finance.yahoo.comOrchestra BioMed Holdings Reports Second Quarter 2024 Financial Results and Business UpdatesAugust 15, 2024 | msn.comOrchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 14, 2024 | finanznachrichten.deBuy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT DevelopmentsAugust 14, 2024 | markets.businessinsider.comOBIO Stock Earnings: Orchestra BioMed Hldgs Misses EPS, Beats Revenue for Q2 2024August 12, 2024 | msn.comSee More Headlines OBIO Stock Analysis - Frequently Asked Questions How have OBIO shares performed this year? Orchestra BioMed's stock was trading at $9.13 at the beginning of 2024. Since then, OBIO stock has decreased by 31.8% and is now trading at $6.23. View the best growth stocks for 2024 here. How were Orchestra BioMed's earnings last quarter? Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.04. The firm had revenue of $0.78 million for the quarter, compared to the consensus estimate of $1.04 million. Orchestra BioMed had a negative net margin of 2,673.26% and a negative trailing twelve-month return on equity of 89.28%. Who are Orchestra BioMed's major shareholders? Top institutional investors of Orchestra BioMed include ABLE Financial Group LLC (0.04%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Darren Sherman, David P Hochman, William Reed Little and Eric S Fain. View institutional ownership trends. How do I buy shares of Orchestra BioMed? Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Orchestra BioMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orchestra BioMed investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/12/2024Today11/05/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:OBIO CUSIPN/A CIK1814114 Weborchestrabiomed.com Phone646-597-6980FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Target$15.75 High Stock Price Target$20.00 Low Stock Price Target$14.00 Potential Upside/Downside+152.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,120,000.00 Net Margins-2,673.26% Pretax Margin-2,673.26% Return on Equity-89.28% Return on Assets-60.64% Debt Debt-to-Equity RatioN/A Current Ratio4.58 Quick Ratio4.58 Sales & Book Value Annual Sales$2.76 million Price / Sales85.39 Cash FlowN/A Price / Cash FlowN/A Book Value$1.90 per share Price / Book3.28Miscellaneous Outstanding Shares37,830,000Free Float35,291,000Market Cap$235.68 million OptionableNot Optionable Beta0.42 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:OBIO) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.